DFV890 for COVID-19: real-time analysis

Download Image

Post

c19early.org

DFV890 for COVID-19

1 study with 142 patients

Serious outcome risk

DFV890

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 DFV890 studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−3%

Mortality (1)−3%

RCTs (1)−3%

Late (1)−3%

00.511.5+

← DFV890
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Sep 14 2022	Madurka et al., Infection, doi:10.1007/s15010-022-01904-w	DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function
Sep 14 2022	3% higher mortality (p=1) and 1% worse recovery (p=0.95). RCT 143 hospitalized patients with COVID-19 pneumonia showing no significant difference in APACHE II scores with DFV890 (NLRP3 inhibitor).